Testing Fludarabine Dosing Before CAR T Therapy in Children and Young Adults With Leukemia
Compares two fludarabine dosing approaches before CAR T therapy in young people with B-cell leukemia.
Plain-language title generated from the registry record
Registry title: A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
Key facts
- Where
- Esplugues de Llobregat, SpainSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young adults with B-cell acute lymphoblastic leukemia who can receive the CAR T-cell therapy tisagenlecleucel. It tests two ways of dosing the chemotherapy fludarabine given before it.
- Age
- 1 Year to 64 Years
- Sex
- All sexes can join.
- Disease stage
- B-cell acute lymphoblastic leukemia (B-ALL), relapsed or not responding to treatment, and able to receive commercial tisagenlecleucel.
Main reasons for not taking part
- Weight of 9 kg (20 lb) or less at the time of chemotherapy before CAR T
- Known allergy or severe reaction to fludarabine, cyclophosphamide or tisagenlecleucel
- Active infection that is not controlled
- Pregnant or breastfeeding women
- Liver, kidney, heart or lung function that is too low
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 64 years old?
Source: NCT07223021, who can take part
Where in Spain
- Hospital Sant Joan De Deu BarcelonaEsplugues de Llobregat, SpainNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Trial code
- NCT07223021EU 2025-523096-34-00
- Record updated
- 12 November 2026
- Original description
The researchers are doing this study to find out whether PK-targeted fludarabine is an effective Lymphodepletion (LD) chemotherapy approach for people with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) who will receive tisagenlecleucel CAR T-cell therapy. The researchers will compare PK-targeted fludarabine dosing with standard fludarabine dosing to see which treatment approach is more effective. The researchers will also look at whether PK-targeted fludarabine dosing is feasible (practical), the side effects of the study treatment, and how the study treatment affects people's quality of life. The researchers will measure quality of life by having participants complete questionnaires.Read full original descriptionShow less
Improving EveNt Free Survival by Optimizing FLUdarabine Exposure During LymphodepletioN for CAR T CEll Therapy: a Randomized, Multi-center Study of Children and Young Adults With B-cell Acute Lymphoblastic Leukemia (INFLUENCE)
The researchers are doing this study to find out whether PK-targeted fludarabine is an effective Lymphodepletion (LD) chemotherapy approach for people with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) who will receive tisagenlecleucel CAR T-cell therapy. The researchers will compare PK-targeted fludarabine dosing with standard fludarabine dosing to see which treatment approach is more effective. The researchers will also look at whether PK-targeted fludarabine dosing is feasible (practical), the side effects of the study treatment, and how the study treatment affects people's quality of life. The researchers will measure quality of life by having participants complete questionnaires.
Inclusion: Patients with B-ALL and eligible to receive commercial tisagenlecleucel; Patient's weight > 9 kg at time of lymphodepleting chemotherapy; Adequate organ function at time of LD is required and is defined:; Hepatic: Serum bilirubin ≤ 2 mg/dL, unless benign congenital hyperbilirubinemia; Hepatic: AST and ALT < 5x the upper limit of normal for age, unless thought to be leukemic disease-related; Renal: Calculated glomerular filtration rate (GFR) ≥ 70 ml/min/1.73m\^2. (based on Schwartz formula GFR (mL/min/1.73 m²) = (36.2 × Height in cm) / Creatinine in mg/dL; Cardiac: LVEF ≥ 50% by multi-gated acquisition scan (MUGA), resting echocardiogram, or cardiac magnetic resonance imaging (MRI) within 6 weeks of screening; Pulmonary: Oxygen saturation as recorded by pulse oximetry of ≥ 90% on room air; Adequate performance status:; Age ≥ 16 years: ECOG ≤ 1 or Karnofsky > 60% at treatment; Age < 16 years: Lansky ≥ 60% at treatment; Willing to participate as research subject and provide written informed consent from parents/legal representative, patient, and age-appropriate assent as appropriate before any study specific screening procedures are conducted, according to local, regional or national law and legislation.
Exclusion: Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to the study drugs, or drugs chemically related to study treatment or excipients that contraindicate their participation, including fludarabine, cyclophosphamide and tisagenlecleucel; Clinically significant active and uncontrolled infection confirmed by clinical evidence, imaging, or positive laboratory tests (e.g., blood cultures, PCR for DNA/RNA etc.); Patients with tisagenlecleucel that is deemed out of specification (OOS) will be excluded from this protocol; Patient/parent/guardian unable to give informed consent or unable to comply with the treatment protocol; Pregnant or lactating women.